Engineering a pathological tau-targeted nanochaperone for selective and synergetic inhibition of tau pathology in Alzheimer's Disease
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Alzheimer's disease research and treatments · Endoplasmic Reticulum Stress and Disease · Heat shock proteins research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (43)
Show source-provided references
1. Alzheimer's disease10.1016/S0140-6736(15)01124-1 ↗
2. Alzheimer’s disease drug development pipeline: 2021
3. Alzheimer mechanisms and therapeutic strategies10.1016/j.cell.2012.02.040 ↗
4. Antiamyloidogenic activity of Aβ42-binding peptoid in modulating amyloid oligomerization10.1002/smll.201770002 ↗
5. The binding of pullulan modified cholesteryl nanogels to Aβ oligomers and their suppression of cytotoxicity10.1016/j.biomaterials.2009.06.010 ↗
6. Self-Assembly molecular chaperone to concurrently inhibit the production and aggregation of Amyloid β peptide associated with Alzheimer’s Disease10.1021/acsmacrolett.8b00495 ↗
7. Self-protecting biomimetic nanozyme for selective and synergistic clearance of peripheral amyloid-β in an Alzheimer’s Disease model10.1021/jacs.0c08395 ↗
8. Alzheimer’s disease: the right drug, the right time10.1126/science.aau0437 ↗
9. The amyloid hypothesis on trial10.1038/d41586-018-05719-4 ↗
10. Why is research on amyloid-β failing to give new drugs for Alzheimer’s Disease?10.1021/acschemneuro.7b00188 ↗
11. Alzheimer disease therapy—moving from amyloid-β to tau10.1038/nrneurol.2013.223 ↗
12. Tau in Alzheimer’s disease: mechanisms and therapeutic strategies10.2174/1567205014666170417111859 ↗
13. Roles of tau protein in health and disease10.1007/s00401-017-1707-9 ↗
14. Tau in physiology and pathology10.1038/nrn.2015.1 ↗
15. Tau protein aggregation in Alzheimer’s disease: an attractive target for the development of novel therapeutic agents10.1016/j.ejmech.2017.07.070 ↗
16. The Hsp70/Hsp90 chaperone machinery in neurodegenerative diseases10.3389/fnins.2017.00254 ↗
17. Tau-targeting therapies for Alzheimer disease10.1038/s41582-018-0013-z ↗
18. A highly connected porous coordination polymer with unusual channel structure and sorption properties10.1002/anie.200901964 ↗
19. Tau-aggregation inhibitor therapy for Alzheimer's disease10.1016/j.bcp.2013.12.008 ↗
20. Tau-centric targets and drugs in clinical development for the treatment of Alzheimer’s disease10.1155/2016/3245935 ↗
21. Modulation of neurodegeneration by molecular chaperones10.1038/nrn1587 ↗
22. Molecular chaperones in protein folding and proteostasis10.1038/nature10317 ↗
23. Neurobiology. Chaperones take flight10.1126/science.1069544 ↗
24. A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease10.1016/j.celrep.2014.09.042 ↗
25. Multifunctional liposomes reduce brain β-amyloid burden and ameliorate memory impairment in Alzheimer's disease mouse models10.1523/JNEUROSCI.0284-14.2014 ↗
26. Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer's disease10.1016/j.jconrel.2017.05.019 ↗
27. Coassembly of macrocyclic amphiphiles for anti-β-Amyloid therapy of Alzheimer’s Disease
28. Recognition and removal of amyloid-β by a heteromultivalent macrocyclic coassembly: a potential strategy for the treatment of Alzheimer’s Disease
29. Polyoxometalates as inhibitors of the aggregation of amyloid β peptides associated with Alzheimer’s disease10.1002/anie.201007067 ↗
30. A biocompatible second near-infrared nanozyme for spatiotemporal and non-invasive attenuation of amyloid deposition through scalp and skull10.1021/acsnano.0c02733 ↗
31. Heat shock protein inspired nanochaperones restore amyloid-β homeostasis for preventative therapy of Alzheimer’s Disease10.1002/advs.201901844 ↗
32. Maintenance of amyloid β peptide homeostasis by artificial chaperones based on mixed-shell polymeric micelles10.1002/anie.201400735 ↗
33. Nanochaperone-based strategies to control protein aggregation linked to conformational diseases10.1002/anie.202007924 ↗
34. Structure-based inhibitors of tau aggregation10.1038/nchem.2889 ↗
35. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins10.1074/jbc.M408714200 ↗
36. Tau-targeted multifunctional nanoinhibitor for Alzheimer’s Disease10.1021/acsami.1c00257 ↗
37. Development of a tau-targeted drug delivery system using a multifunctional nanoscale metal-organic framework for Alzheimer’s Disease therapy10.1021/acsami.0c11064 ↗
38. Targeting tauopathy with engineered tau-degrading intrabodies10.1186/s13024-019-0340-6 ↗
39. Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules10.1038/nm0796-783 ↗
40. Modeling prion-like processing of tau protein in Alzheimer’s disease for pharmaceutical development10.3233/JAD-170727 ↗
41. Major differences between the self-assembly and seeding behavior of heparin-induced and in vitro phosphorylated tau and their modulation by potential inhibitors10.1021/acschembio.9b00325 ↗
42. Tau-targeted multifunctional nanocomposite for combinational therapy of Alzheimer’s Disease10.1021/acsnano.7b07625 ↗
43. Blood-brain barrier-penetrating siRNA nanomedicine for Alzheimer's disease therapy10.1126/sciadv.abc7031 ↗